About PGDx

Management Team

Douglas Ward
Douglas Ward
Chief Executive Officer
Mr. Doug Ward joined Personal Genome Diagnostics as Chief Executive Officer and a member of the board of directors in May 2016 from Roche, where he served as Vice President Companion Diagnostics (CDx) for Ventana Medical System. He has more than 25 years of experience within the diagnostic market and most recently has been responsible for creating Ventana’s CDx strategy, establishing Ventana’s innovative pharma partnering co-development business model, and achieving the market leading position in tissue based companion diagnostics. Prior to joining Roche, Mr. Ward served as President of the America’s Commercial Operations for GE Healthcare Life Sciences Business. Previously, he was Country Head of the UK and Ireland for Siemens Healthcare Diagnostics and Vice President of Marketing and Scientific Affairs for Bayer Diagnostics’ Molecular Diagnostics business unit. In addition, he has held leadership positions with Chiron Diagnostics and Ciba Corning Diagnostics. Doug received his BA from Ohio Wesleyan University in Pre-Medicine and Pre-Professional Zoology.
Samuel Angiuoli
Samuel Angiuoli, PhD
Chief Information Officer
Dr. Samuel Angiuoli is a computer scientist with over a decade of experience in bioinformatics and a deep understanding of the information technology challenges associated with genomics. Prior to joining PGDx, Dr. Angiuoli directed bioinformatics teams at leading genome sequencing facilities, including The Institute for Genomic Research, J. Craig Venter Institute, and the Institute for Genome Sciences at the University of Maryland, School of Medicine. Dr. Angiuoli received a PhD in computer science from the University of Maryland and a B.S. with distinction from Duke University majoring in both chemistry and computer science.
Jack Crowley
Jack Crowley, CPA, MBA
Chief Financial Officer
Mr. Jack Crowley brings more than 25 years of finance and operations experience to PGDx, previously serving as Chief Financial Officer and Treasurer at Lantheus with responsibility for all finance, information technology, and investor relationship activities. He led transformational recapitalization efforts following Lantheus’ IPO in 2015, and his prior roles at the company included Chief Accounting Offer, Vice President of Finance, and Global Corporate Controller. Before joining Lantheus, Mr. Crowley served as Director of Finance and Assistant Corporate Controller of Biogen Idec, the Director of Accounting at Thermo Fischer Scientific, and a Senior Manager in the Audit practice of PricewaterhouseCoopers LLP. Mr. Crowley, who is a Certified Public Accountant, holds a Master of Business Administration from the University of Massachusetts and a Bachelor of Science in Business Administration from Westfield State University.
Megan Bailey
Megan Bailey, MPH
Vice President, Marketing
Megan Bailey joined Personal Genome Diagnostics in March of 2018 as Vice President of Marketing from Roche Diagnostics where she held several roles of increasing responsibility. Most recently she served as Senior Director of Commercial Operations, responsible for leading sales teams across Roche’s Clinical Chemistry/Immunoassay, Molecular, Tissue, and Point of Care divisions in the Southeast United States. Prior to that she held marketing leadership roles for the Tissue Diagnostics division (Ventana Medical Systems) where she led multiple product launches, developed and executed commercial strategies across a variety of product lines, and drove strategic collaborations with some of the nation’s largest Integrated Health Networks. She comes to PGDx with more than 15 years of experience in the diagnostics industry and a passion for improving patient care in oncology. Megan earned her Bachelor’s degree in English with a minor in Systems Engineering from the United States Military Academy at West Point and her Master of Public Health from the University of North Carolina – Chapel Hill.
Jennifer Dickey
Jennifer Dickey, PhD, RAC
Vice President, Regulatory & Quality

Dr. Jennifer Dickey, PhD, RAC has joined PGDx as Vice President of Regulatory and Quality.  Dr. Dickey comes with an impressive background having most recently been with the FDA as Senior Scientific Reviewer in the Molecular Genetics branch of the Office of In Vitro Diagnostics and Radiological Health. Dr. Dickey has more than 7 years of regulatory review experience and was Regulatory Affairs Certified (RAC) through the Regulatory Affairs Professional Society (RAPS) in 2012. Dr. Dickey has played a leadership role in several regulatory initiatives including serving as Chair of the Next Generation Sequencing-based Oncology Panels Public Workshop (February 25, 2016) and as lead reviewer for the first NGS-based assay (Illumina assay for cystic fibrosis).  Dr. Dickey has spoken at several association conferences on subjects such as Regulatory Review of NGS Assays; Potential Roles for NGS in Companion Diagnostics; FDA Review of NGS Technologies; Multi-Analyte NGS Assays; and Enabling NGS in Global Clinical Trials, additionally Dr. Dickey has co-authored numerous peer-reviewed articles.

Jay Foust
Jay Foust, MBA
Senior Vice President, Business Development
Jay Foust joined Personal Genome Diagnostics as Senior Vice President of Business Development in August of 2017 from Ventana Medical Systems, where for ten years he held multiple roles spanning corporate development, strategic marketing, and business development. He has significant negotiating experience with third parties, having completed dozens of licenses, several mergers and acquisitions, and more than 300 contracts with more than 100 pharma partners. Prior to Ventana, Jay spent ten years with Research Corporation Technologies, a venture capital firm, where he helped companies bring FDA-approved drugs, medical devices, and diagnostic tests to market. He brings significant project and product development experience to PGDx, and is passionate about helping cancer patients. Jay graduated from the University of Arizona with a Bachelor of Science in Molecular and Cell Biology as well as an MBA in Finance.
Siân Jones
Siân Jones, PhD
Vice President, Genome Sciences
Dr. Sian Jones was a member of the Johns Hopkins University team that sequenced a cancer genome for the first time, and has since used this approach at PGDx to identify genes with critical roles in a range of tumor types. She leads the team that analyzes sequence data where the goal is to provide meaningful information to aid in interpreting results of these complex analyses. Previously, she was a Post-doctoral Fellow at the Ludwig Center for Cancer Genetics and Therapeutics. Dr. Jones earned a Ph.D. in Cancer Genetics from Cardiff University.
James Lewis
James Lewis, MBA
Senior Vice President, Corporate Development

Mr. James Lewis joined Personal Genome Diagnostics as Senior Vice President, Corporate Development in November 2016 from Esperance Pharmaceuticals, where he served as Vice President, Business Development and a member of the management team.  Jim is a life science industry executive with more than 25 years of growth-oriented corporate leadership experience across a spectrum of strategic planning, general management, business development, fundraising and commercial roles at companies including AstraZeneca, plc., Biosyn, Inc., ViroPharma, Inc. and TAP Pharmaceuticals.  Jim has also recently served as a business advisor and consultant for emerging stage life science companies including Jenrin Discovery, Zelos Therapeutics, Amorcyte, Inc. and Azur Pharma. 

Abigail McElhinny
Abigail McElhinny
Senior Vice President, Research & Development and Operations
Dr. Abigail McElhinny joined Personal Genome Diagnostics as Senior Vice President, Research & Development and Operations in May 2016 from Ventana Medical Systems (Roche Tissue Diagnostics), where she held a number of different roles of increasing responsibilities. At Ventana, Abigail held the position as Vice President of Assay and Reagent Development where she built and led Research & Development teams with the goal of developing new assays for the BenchMark and next generation platforms. Dr. McElhinny represented Ventana on the pivotal PD-L1 Blueprint initiative, and successfully oversaw key scientific projects critical to the business, while her organization doubled in size. Abigail previously served as Senior Project Leader for CDx lifecycle projects, working with regulatory, clinical affairs, quality, and biostatistics teams to build the necessary processes and requirements to support pharma clinical trials and obtain FDA approval for CDx assays, including Ventana’s ALK (D5F3) CDx IHC assay and HER2 Dual ISH assays. Abigail received her Ph.D from Northeastern University in Immunology and Biochemistry, and completed a post-doctoral fellowship at University of Arizona in Cell Biology, focused on molecular mechanisms of cardiac muscle development, cardiomyopathies and muscle remodeling.
Mary Padilla, MD
Mary Padilla, MD
Vice President, Clinical Operations

Dr. Mary Padilla has joined PGDx as Vice President of Customer Service and Support.  Dr. Padilla will play a major role in building a team and infrastructure for supporting PGDx reagent and software products that are on the market and in the PGDx CLIA lab.  Previously, Mary most recently served as General Manager for Spring Bioscience and Discovery for Instruments at Roche Tissue Diagnostics.  Dr. Padilla has extensive experience supporting both Research & Development as well as diagnostic commercialization.   Dr. Padilla received a BA degree in Biochemistry and Anthropology as well as earning MD, and completing residency training in Pathology at the University of Arizona.  Dr. Padilla spent her fellowship years at the University of Chicago.  Dr. Padilla also spent 2 years in Barcelona, Spain, with her family, where she traveled globally to support CDx products and was appointed Medical Director of Companion Diagnostics.

John Simmons
John Simmons, PhD
Vice President, Translational Medicine

Dr. John Simmons joined Personal Genome Diagnostics in 2016 and serves as the Vice President of Translational Medicine. In this role, John focuses broadly on scientific strategy and diagnostics partnerships with pharma/biotech.  Previously, John was at the National Cancer Institute where his research focused on identifying novel therapeutic strategies for multiple myeloma through chemical genomic approaches with a particular focus on drug combinations. He received his undergraduate degree in Biology with honors from American University and Ph.D. in Tumor Biology from Georgetown University as part of the NIH Graduate Partnership Program. As a post-doctoral fellow, he received the Multiple Myeloma Research Foundation (MMRF) Research Fellow award to support his work in developing systems-level approaches for drug combination identification and prioritization.